Drug recall · February 5, 2014
MaXtremeZEN capsules recall
Why: Marketed Without An Approved NDA/ANDA: FDA analysis found MaXtremeZEN which is marketed as a dietary supplement to contain undeclared desmethyl carbondenafil and dapoxetine. Desmethyl carbondenafil is a phosphodiesterase (PDE)-5 inhibitors which is a class of drugs used to treat male erectile dysfunction, making this product an unapproved new drug. Dapoxetine is an active ingredient not approved
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
MaXtremeZEN capsules, 1 capsule per blister pack, Distributed by: P&A Enterprise, Buena Park, CA 90621, UPC 6 10079 52468 2.
- Lots / codes
Lot #: JBP-L-1270-70, Exp 12/16
- Quantity
- 2,395 blister packs total for all products
- Company
- SS Wholesale Inc. dba Jobbers Wholesale, Paramount, CA
- Distribution
- CA
- Initiated
- November 18, 2013 · Voluntary: Firm initiated
- Classified
- January 30, 2014
- Reported
- February 5, 2014
- Ended
- May 9, 2014
- How notified
- Press Release
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.